NEUN - NeuroGenesis NEUN Company Description After

New Post Public Reply Private Reply Replies (2) Message Board
PYCKtradr
NEUN - NeuroGenesis



NEUN Company Description
After additional intense research, NeuroGenesis, a supplement formulator discovered that the Neu BeCalm'd approach is the most effective means of providing a long lasting solution to chemical imbalances in the brain. While most types of traditional medicine treat the symptoms, the Neu BeCalm'd product addresses the underlying issues in order help one achieve a normal life. In addition, the Neu BeCalm'd formulation contains FDA approved nutritional ingredients. Neu BeCalm'd has been reported to be beneficial in reducing the effects of acute as well as chronic stress factors in those who use the product.

Neu BeCalm'd is a safe, all natural alternative to traditional medicine, and is intended for people with PTSD and other similar problems. In addition, Neu BeCalm'd contains formulations of vitamins, minerals and amino acids that are designed to assist the brain in balancing and rebuilding neurotransmitters to achieve and maintain a chemical balance.



NEUN Products and Services
The goal of our products is to improve the availability and balance of certain chemicals in the brain called neurotransmitters. These chemicals, neurotransmitters, attach to various brain cells in the brain and, depending on the location, produce what we call thoughts or feelings or actions. When these chemicals are depleted somewhat or are “out of balance with each other” then our thoughts or feelings or actions are effected in negative ways. We may have inappropriate thoughts, feel depressed, and do things we would not normally do.

Over the years research has shown us that trauma (stress) as well as the use of certain medications or other drugs can cause serious shortages of these transmitters.
NeuroGenesis set out to produce products that would assist directly with the manufacture of the desired transmitters to such levels that balance could occur and normal thoughts, feelings and actions could be restored. Transmitters in the brain are made from amino acids in the presence of specific vitamins and minerals which serve as co-factors in this building process.

While there are literally hundreds of transmitters in the brain research has shown that there are just a few that are extremely important for quality of thought, feeling and actions. The first of these is dopamine, a chemical which works to produce feelings of happiness, love, attachment, concern for others. Dopamine is produced from L-phenylalanine in our products.

The next is norepinepherine which works to energize use, to tell our hearts to beat and our lungs to expand. This transmitter is also made from the amino acid L-phenylalanine.
Third is serotonin, an extremely important transmitter in several places in the brain. This transmitter functions to keep our emotions in balance so that we are not up and down all the time. It also facilitates all our sensory input (sight, sound, touch, smell, and taste) to various areas of the brain for interpretation and communication. This transmitter is important in the sleep cycle as well as other rhythmic cycles our bodies experience. Serotonin is produced from 5-HTP in our products.

Next is GABA (Gamma amino butyric acid) which is the brains most important calming agent. GABA works to keep transmitter firings in balance so that our thoughts don’t “race”. When GABA is effective we don’t feel “anxiety” all the time for seemingly no reason. This important calming agent is produced by L-glutamine in our products.

Last, and far from least, is a group of transmitters called “peptides” (because they consist of five amino acids). These transmitters are of the “opiate or opioid” family and work to reduce the effect of physical pain as well as create a sense of internal calm and completeness. When these transmitters are effective our sense of positive self concept is high, we feel good within ourselves. When deficiencies occur our pain threshold is lowered and we have a deep sense of inadequacy.

The opioids are produced by a combination of aminos in our products, especially when NeuBecalm’d and NeuRelieve are combined. These peptides are a combination of the amino acids L-phenylalanine, L-tyrosine (which is made from L-phenylalanine), 2 molecules of the amino L-glycine and the amino acid methionine (made available by the actions of folic acid in our products.)

When trauma or drug use occurs no single transmitter is depleted but all of the transmitters in the effected area are limited. It is important to use a well balanced supplement which will work to reestablish the desired balance for optimum effect.



NEUN Key Company Management
Albert H. Bieser serves as Chairman, President and Chief Executive Officer of Neurogenesis Inc. Mr. Bieser served as Chief Financial Officer and Treasurer of Neurogenesis. Prior to 1984, Mr. Bieser served as the President of B. E. Industries, Inc., a successful private company that manufactured ship board satellite antenna aiming systems, President of General Computer Systems, Inc. a publicly held firm which manufactured a proprietary 'key-disk-tape' data entry subsystem and as Managing Director of Recognition Equipment-Europe,a computer related company. He holds Bachelor of Science Degrees in Business Administration (1953) and Electrical Engineering (1959) from the University of Colorado. He also holds a Master of Science Degree in Electrical Engineering from Southern Methodist University (1963).


NEUN Contact Info
NeuroGenesis, Inc.
120 Park Ave.
League City, TX 77573

Website: http://www.neurogenesis.com
Phone: 281-557-7877

NEUN SEC Filings
http://www.otcmarkets.com/stock/NEUN/filings

NEUN Headlines
http://finance.yahoo.com/q/h?s=NEUN+Headlines

Investigate more about NEUN @ http://www.otcmarkets.com/stock/NEUN/quote for more due diligence.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Infosys Pushes AI Growth with Strong Deal Wins

Updated Category News Views 17

Riding the AI Wave Who knew Infosys was a lightning rod for AI momentum, eh? With a 29% quarterly surge in AI revenue, the firm's really putting AI strategy at center stage. Considering today's finicky markets, that's not just peanuts. CEO Salil Parekh's swagger is backed by real numbers, seeing AI revenue inch to 10.5% of total haul. This ain't just talk—Infosys is...

Continue Reading
PZZA Faces Class Action: Strategic Shake-up or Misstep?

Updated Category News Views 10

Papa John's: Doughy Deceit or Strategic Misfire? Once in a while, a corporation trips over its own ambitious production line, and Papa John’s (NASDAQ:PZZA) is the latest contestant to make headlines for all the wrong reasons. Investors in this pizza powerhouse are being called to the courtroom as a class action lawsuit unfolds, marking a turbulent stage in the...

Continue Reading
FDA Nod for Subcutaneous SKYRIZI in Crohn's Disease

Updated Category News Views 48

AbbVie's Injection Makes Waves in Crohn's Treatment Here's a bit of medicine shake-up for you. AbbVie just snagged FDA approval for its subcutaneous SKYRIZI—specifically designed for adults battling moderately to severely active Crohn's disease. This news isn't just a blip on the radar; it's significant for patients and the healthcare landscape. We're talking about new...

Continue Reading
Honeywell Aerospace Faces Class Action: Deadline Looms

Updated Category News Views 37

Navigating the Legal Storm with Honeywell Look, investors never have it easy, and when lawsuits start flying like today's news about Honeywell Aerospace, you better have your wits about you. Now here comes Kahn Swick & Foti, LLC, ringing the alarm bells. Any holders of Honeywell Aerospace stocks between late June and early September of '26 are squarely in the spotlight....

Continue Reading
SLM Faces Legal Scrutiny as Losses Mount Amid Pause

Updated Category News Views 36

SLM's Latest Troubles: Legal and Financial Impact Ah, student loans—not just a headache for borrowers but now for lenders too. SLM Corporation, that name we know all too well in the student debt circus, has hit a snag. They've paused most of their third-party recovery activities. Let's dig in: net charge-offs for SLM in the third quarter shot up to a hefty $90.4...

Continue Reading
Pathalys' Phase 3 Data Shows Promise for CKD Drug

Updated Category News Views 30

A Glimpse at Pathalys Pharma's Recent Win This is some groundbreaking stuff emerging from Pathalys Pharma. Their investigational drug, upacicalcet, has just clinched a significant victory in two crucial Phase 3 trials - PATH-1 and PATH-2 - aimed at treating Secondary Hyperparathyroidism (SHPT) in patients with end-stage kidney disease undergoing hemodialysis. With SHPT...

Continue Reading
Stephen A. Smith Calls for Corporate Support of HBCUs

Updated Category News Views 4

A Stand for Education at the White House Stephen A. Smith stirred the pot with his decision to attend a White House dinner, a move that had tongues wagging across the media landscape. But this time, it wasn't about the usual hustle and bustle of the sports world. Smith had his sights set on the big picture, specifically, the long-term financial stability of Historically...

Continue Reading
Violet PR's Big Wins Hint at Industry Strategies

Updated Category News Views 15

A Shining Night in Morristown Picture Violet PR's team on top of the world, right there in Morristown, getting the accolades every agency dreams of—five awards from PRSA-NJ. It's not just an ego trip, either. This is about setting a high bar in the world of strategic communications, and they're flaunting their ability to drive growth and innovation in the economic...

Continue Reading
BOB Raises $5.5M for AI Banking Platform Revolution

Updated Category News Views 24

Cracking the Code of Small Business Finance BOB, a Miami hotshot aiming to be more than just another fintech flash in the pan, has wrangled a sweet $5.5 million in seed capital. They're shaking hands with big names like Peter Thiel and the mastermind behind Plaid, Zak Perret, through Mischief Ventures. The plan? To build an AI-powered finance savior for small businesses...

Continue Reading
GeeLark's Tech Leap: Expanding Cloud Phone Functions

Updated Category News Views 3

GeeLark's New Frontier GeeLark is kicking up some dust in the tech space by tooling up its cloud phone workflows with an arsenal of new supports: API, CLI, and MCP. This isn't just some minor patch, folks. It's a bold move, and for those in the quicksand of digital operations, a game-changer. You know how much of a drag it is repeating the same setup steps over and over?...

Continue Reading

Top 5 Most Recently Viewed Articles

CoinW Showcases Its Innovations at Taipei Blockchain Week 2024

Updated Category News Views 261

CoinW's Impactful Presence at Taipei Blockchain Week 2024 At the forefront of innovation and security, CoinW, a globally recognized cryptocurrency exchange, recently showcased its vision for the future during Taipei Blockchain Week 2024 as a Gold Sponsor. The event, celebrated for fostering discussions on blockchain advancements, featured the launch of PropW, CoinW's...

Continue Reading
Bank of Åland Plc Seeks Trading Admission of New Covered Bonds

Updated Category News Views 170

Application for Trading Admission of Covered Bonds Bank of Åland Plc, also recognized as Ålandsbanken Abp, is taking an important step by applying for the admission of a new security to trading on Nasdaq Helsinki. This involves their recent issuance of covered bonds, which are highly regarded in the financial market. Details of the Covered Bonds Issue The primary...

Continue Reading
Simpson Manufacturing's Q3 Earnings Report Shows Challenges Ahead

Updated Category News Views 54

Simpson Manufacturing's Third Quarter Performance Simpson Manufacturing Co., Inc. (NYSE: SSD) recently announced its third-quarter earnings, and the results did not meet the expectations of analysts. This disappointing performance resulted in a 5% decline in shares during after-hours trading. The company's focus on producing wood construction products highlights the...

Continue Reading
Alvotech Faces Challenges in Biologics License Approval Process

Updated Category News Views 349

Overview of Biologics License Application Status Alvotech, a prominent biotech firm specializing in biosimilars, has recently updated the market regarding its application status for AVT05, a potential competitor to Simponi (golimumab). The company has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) highlighting certain...

Continue Reading
Replimune Group Faces Class Action Lawsuit Amid FDA Setback

Updated Category News Views 127

Replimune Group Faces Class Action Lawsuit Amid FDA Setback Pomerantz LLP has brought attention to a class action lawsuit involving Replimune Group, Inc. (NASDAQ: REPL). This legal action is relevant for investors who have experienced losses on their investments in the company. It's crucial for affected investors to be proactive and consider their options as they navigate...

Continue Reading